Abstract WMP3: DEFUSE-3 Eligible but DAWN Ineligible Patients Treated Within 16-24 Hours: Results From BEST Prospective Cohort Study

• Published in: Stroke (1970) 2019-02, Vol.50 (Suppl_1)
• Main Authors: Mistry, Eva A, Sucharew, Heidi, Mehta, Tapan, Arora, Niraj, Starosciak, Amy, De Los Rios La Rosa, Felipe, Siegler, James E, Barnhill, Natasha, Mistry, Akshitkumar M, Patel, Kishan, Assad, Salman, Tarboosh, Amjad, Dakay, Katarina, Wagner, Jeff, Cruz, Aurora, Fortuny, Enzo, James, Robert, Jagadeesan, Bharathi, Streib, Christopher, Weber, Stewart, Chitale, Rohan, Volpi, John J, Mayer, Stephan, Yaghi, Shadi, Jayaraman, Mahesh, Khatri, Pooja
• Format: Article
• Language: English
• ISSN: 0039-2499; 1524-4628
• DOI: 10.1161/str.50.suppl_1.WMP3

Abstract only Background: The 2018 ASA guidelines recommend endovascular stroke treatment (EVT) for patients who meet DEFUSE 3 (D3) trial criteria within 6-16 hrs and those who meet DAWN criteria within 6-24 hrs of last known well (LKW). Recommendation to use more restrictive DAWN and not D3 criteria between 16 and 24 hrs is not strictly followed in clinical practice. Using the prospective multi-institutional cohort study, “Blood Pressure after EVT (BEST),” we determined the frequency and outcomes of EVT-treated patients within the 16-24 hrs of LKW who met D3 but not DAWN criteria. Methods: BEST enrolled consecutive EVT-treated adult patients with ICA, M1, or M2 occlusions at 12 comprehensive stroke centers from 11/2017 to 7/2018. D3-but not DAWN-eligible patients were defined as those with ICA/M1 occlusions, a mismatch volume 15cc, and any of the following: 1) NIHSS 6-9, 2) infarct core 51-70 cc, 3) age 80 yrs and infarct core 21-70 cc, or 4) NIHSS 11-19 , age